Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic.

Montaner JS, Hogg R, Wood E, Kerr T, Tyndall M, Levy AR, Harrigan PR.

Lancet. 2006 Aug 5;368(9534):531-6. Review. No abstract available.

PMID:
16890841
2.

HIV prevention and treatment in Africa.

Laurence J.

AIDS Patient Care STDS. 2000 Aug;14(8):399-400. No abstract available.

PMID:
10977967
3.

Expanded access to highly active antiretroviral therapy: a potentially powerful strategy to curb the growth of the HIV epidemic.

Lima VD, Johnston K, Hogg RS, Levy AR, Harrigan PR, Anema A, Montaner JS.

J Infect Dis. 2008 Jul 1;198(1):59-67. doi: 10.1086/588673.

4.

Global situation of the HIV/AIDS pandemic, end 2003. Part II: Estimating ARV global treatment needs (2003-2005).

[No authors listed]

Wkly Epidemiol Rec. 2003 Dec 12;78(50):426-30. English, French. No abstract available.

PMID:
14702672
5.

Does antiretroviral therapy prevent HIV transmission to sexual partners?

Lalani T, Hicks C.

Curr HIV/AIDS Rep. 2007 May;4(2):80-5. Review.

PMID:
17547829
6.

Balancing effectiveness and access to HIV treatment in the developing world.

Hill A, Wood E.

AIDS. 2007 Jan 30;21(3):361-3. No abstract available.

PMID:
17255743
7.

The potential impact of expanding antiretroviral therapy and combination prevention in Vietnam: towards elimination of HIV transmission.

Kato M, Granich R, Bui DD, Tran HV, Nadol P, Jacka D, Sabin K, Suthar AB, Mesquita F, Lo YR, Williams B.

J Acquir Immune Defic Syndr. 2013 Aug 15;63(5):e142-9. doi: 10.1097/QAI.0b013e31829b535b.

8.

Global AIDS conference finds the issue is cash.

Cullinan K.

Bull World Health Organ. 2002;80(9):761-2. No abstract available.

9.
10.

The evolving landscape of the economics of HIV treatment and prevention.

Nosyk B, Montaner JS.

PLoS Med. 2012 Feb;9(2):e1001174. doi: 10.1371/journal.pmed.1001174. No abstract available.

11.

The high cost of second-line antiretroviral therapy for HIV/AIDS in South Africa.

Long L, Fox M, Sanne I, Rosen S.

AIDS. 2010 Mar 27;24(6):915-9. doi: 10.1097/QAD.0b013e3283360976.

PMID:
20042849
12.

The economic viability of antiretroviral adherence interventions.

Bozzette SA, Gifford AL.

Am J Med. 2003 Dec 1;115(8):672-3. No abstract available.

PMID:
14656623
13.

Is antiretroviral therapy cost-effective in South Africa?

Braithwaite RS, Tsevat J.

PLoS Med. 2006 Jan;3(1):e60. No abstract available.

14.

Long-term impact of highly active antiretroviral therapy on HIV-related health care costs.

Keiser P, Nassar N, Kvanli MB, Turner D, Smith JW, Skiest D.

J Acquir Immune Defic Syndr. 2001 May 1;27(1):14-9.

PMID:
11404515
15.

A resurgent HIV-1 epidemic among men who have sex with men in the era of potent antiretroviral therapy.

Bezemer D, de Wolf F, Boerlijst MC, van Sighem A, Hollingsworth TD, Prins M, Geskus RB, Gras L, Coutinho RA, Fraser C.

AIDS. 2008 May 31;22(9):1071-7. doi: 10.1097/QAD.0b013e3282fd167c.

PMID:
18520351
16.

AIDS prevention more cost-effective than HAART treatment.

[No authors listed]

AIDS Policy Law. 2002 Jun 7;17(11):2. No abstract available.

PMID:
12083037
17.

Providing antiretroviral therapy for HIV infection.

Steinbrook R.

N Engl J Med. 2001 Mar 15;344(11):844-6. No abstract available.

PMID:
11248164
18.

Antiretroviral therapy in children--increased benefit from increased complexity.

Cotton MF.

S Afr Med J. 2000 Oct;90(10):985-8. Review. No abstract available.

PMID:
11081099
19.

The Brazilian experiment: HIV drugs for all.

Flaer PJ, Younis MZ.

J Health Care Finance. 2009 Winter;36(2):90-6.

PMID:
20499725
20.

Effectiveness and cost-effectiveness of strategies to expand antiretroviral therapy in St. Petersburg, Russia.

Long EF, Brandeau ML, Galvin CM, Vinichenko T, Tole SP, Schwartz A, Sanders GD, Owens DK.

AIDS. 2006 Nov 14;20(17):2207-15.

PMID:
17086061
Items per page

Supplemental Content

Support Center